The DOI matches its Crossref record; 24 of the 29 references it cites were found in a registry or an index.
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study
Open accessAbstract
Aim: To evaluate the efficacy and safety of celecoxib combined with chemotherapy in the treatment of metastatic or postoperative recurrent gastric cancer. Methods: This preliminary, three-center, clinical trial study was conducted between September 2010 and December 2016. In the experimental group (n = 100), patients were treated with celecoxib combined with chemotherapy, and chemotherapy alone was used in the control group. Progression-free survival (PFS) was considered as the primary efficacy parameter. Overall survival (OS), remission rate (RR), quality of life (QOL) and drug safety were considered as the secondary efficacy parameters. Results: The PFS of the experimental group was 6 months, which was not significantly longer than that of the control group (5 months, P = .73). The average OS was not significantly different between the experimental group (12 months) and the control group (10 months, P = .59). The average OS of the COX-2 positive patients in the experimental group was 14 months and it was significantly longer than the 10-month OS in the control group (P = .01). The PFS of the COX-2 positive patients in the experimental group was 7.5 months, significantly longer than the 5-month PFS of patients in the control group (P < .001). No statistical significance was identified in the incidence of nausea, neutropenia, anorexia, peripheral neurotoxicity, diarrhea, vomiting, asthenia and thrombocytopenia. The EORTC QLQ-C30 questionnaire revealed that the overall QOL of the experimental group was significantly higher than that of the control group (P < .05). No statistical significance was found in the scores of functioning scale between the 2 groups. However, the scores of the symptom scale, especially for pain and fatigue in the experimental group was remarkably higher than that in the control group (P < .05). The overall score of EORTC QLQ-STO22 for the experimental group was considerably higher compared to that for the control group (P < .05). No statistical significance was identified in term of the domains of restrictions on feeding, dysphagia, anxiety, reflux, sense of taste, dry mouth, hair loss and body shape between the 2 groups (P > .05 for all mentioned outcomes). Conclusion: Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Guo et al. demonstrated that administration of celecoxib post-diagnosis led to better overall survival rates in cancer patients, particularly those exhibiting positive PTGS2 expression combined with a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation.185”
From Drug repurposing for cancer therapy (2024) · cites this paper as [185]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Lim, H. Y., Joo, H. J., Choi, J. H., Yi, J. W., Yang, M. S., Cho, D.-Y., Kim, H. S., Nam, D. K., Lee, K. B., & Kim, H. C. (2000) · PubMed · Cited by 249
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 154
Cyclooxygenase‐2 expression during carcinogenesis in the human stomach
van Rees, B. P., Saukkonen, K., Ristimaki, A. P., Polkowski, W. P., Tytgat, G. N. J., Drillenburg, P., & Offerhaus, G. J. A. (2001) · The Journal of Pathology · doi:10.1002/path.1033 · Cited by 153
Saukkonen, K., Nieminen, O., van Rees, B. P., Vilkki, S., Härkönen, M., Juhola, M. T., Mecklin, J., Sipponen, P., & Ristimaki, A. P. (2001) · PubMed · Cited by 141
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 116
Nakata, E., Mason, K. A., Hunter, N. R., Husain, A., Raju, U., Liao, Z. X., Ang, K. K., & Milas, L. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.061 · Cited by 94
Liu, M., Li, C., Chen, Z., JI, R., Guo, Q., Li, Q., Zhang, H., & Zhou, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1713 · Cited by 72
Self-citationScreening and Early Detection of Gastric Cancer
Suh, Y., & Yang, H. (2015) · Surgical Clinics of North America · doi:10.1016/j.suc.2015.05.012 · Cited by 68
Jackisch, C., Lammers, P. E., & Jacobs, I. A. (2017) · The Breast · doi:10.1016/j.breast.2017.01.010 · Cited by 47
Mondello, P., Brea, E. J., de Stanchina, E., Toska, E., Chang, A. Y., Fennell, M., Seshan, V., Garippa, R. J., Scheinberg, D. A., Baselga, J. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90196 · Cited by 47
Research works printed but not linked: 1
- Tang, 2015, Advances in the treatment of gastric cancer with non-cytotoxic drugs, Chin J Pract Intern Med, 12, 1062
Cited by
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
Lanser, L., Kink, P., Egger, E. M., Willenbacher, W., Fuchs, D., Weiss, G., & Kurz, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00249 · Cited by 169
Li, S., Jiang, M., Wang, L., & Yu, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110389 · Cited by 166
Wang, D., Cabalag, C. S., Clemons, N. J., & DuBois, R. N. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.09.059 · Cited by 169
Targeting inflammation as cancer therapy
Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 135
Metadata
- Authors
- Guo, Q., Li, Q., Wang, J., Liu, M., Wang, Y., Chen, Z., Ye, Y., Guan, Q., & Zhou, Y.
- Affiliations
- Department of Gastroenterology
- First Hospital of Lanzhou University (CN)
- Corresponding author
- Zhou, Yongning
- Venue
- Medicine
- Published
- 2019-07
- Volume
- 98
- Issue
- 27
- Pages
- e16234
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC6635161
- OpenAlex
- W2956263305
- Cited by
- 53
- References
- 29
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 12 · 2019: 1
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- celecoxib, gastric cancer, metastatic gastric cancer, recurrent gastric cancer, COX-2 inhibition, combination chemotherapy, progression-free survival, overall survival, quality of life, drug safety, COX-2 expression, postoperative recurrence, EORTC QLQ-C30, neutropenia
- MeSH terms
- Celecoxib, Capecitabine, Oxaliplatin, Adolescent, Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Tegafur, Gastrectomy, Humans, Injections, Intravenous, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Retrospective Studies, Stomach Neoplasms, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. https://app.cochat.ai/papers/10.1097/md.0000000000016234
- The paper
- Guo, Q., Li, Q., Wang, J., Liu, M., Wang, Y., Chen, Z., Ye, Y., Guan, Q., & Zhou, Y. (2019). A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. Medicine. https://doi.org/10.1097/md.0000000000016234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.